Cargando…

Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region

BACKGROUND: Most patients treated with erenumab in clinical practice have chronic migraine (CM). We assessed the rate and possible predictors of conversion from CM to episodic migraine (EM) in a real-life study. MAIN BODY: We performed a subgroup analysis of patients treated with erenumab from Janua...

Descripción completa

Detalles Bibliográficos
Autores principales: Ornello, Raffaele, Casalena, Alfonsina, Frattale, Ilaria, Caponnetto, Valeria, Gabriele, Amleto, Affaitati, Giannapia, Giamberardino, Maria Adele, Assetta, Maurizio, Maddestra, Maurizio, Marzoli, Fabio, Viola, Stefano, Cerone, Davide, Marini, Carmine, Pistoia, Francesca, Sacco, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429460/
https://www.ncbi.nlm.nih.gov/pubmed/32799790
http://dx.doi.org/10.1186/s10194-020-01171-w
_version_ 1783571267602874368
author Ornello, Raffaele
Casalena, Alfonsina
Frattale, Ilaria
Caponnetto, Valeria
Gabriele, Amleto
Affaitati, Giannapia
Giamberardino, Maria Adele
Assetta, Maurizio
Maddestra, Maurizio
Marzoli, Fabio
Viola, Stefano
Cerone, Davide
Marini, Carmine
Pistoia, Francesca
Sacco, Simona
author_facet Ornello, Raffaele
Casalena, Alfonsina
Frattale, Ilaria
Caponnetto, Valeria
Gabriele, Amleto
Affaitati, Giannapia
Giamberardino, Maria Adele
Assetta, Maurizio
Maddestra, Maurizio
Marzoli, Fabio
Viola, Stefano
Cerone, Davide
Marini, Carmine
Pistoia, Francesca
Sacco, Simona
author_sort Ornello, Raffaele
collection PubMed
description BACKGROUND: Most patients treated with erenumab in clinical practice have chronic migraine (CM). We assessed the rate and possible predictors of conversion from CM to episodic migraine (EM) in a real-life study. MAIN BODY: We performed a subgroup analysis of patients treated with erenumab from January 2019 to February 2020 in the Abruzzo region, central Italy. Treatment was provided according to current clinical practice. For the purpose of the present study, we included patients fulfilling the definition of CM for the three months preceding erenumab treatment and with at least 6 months of follow-up after treatment. We assessed the rate of conversion to EM from baseline to Months 4–6 of treatment and during each month of treatment. To test the clinical validity of conversion to EM, we also assessed the decrease in monthly headache days (MHDs), acute medication days, and median headache intensity on a Numerical Rating Scale (NRS). We included in our study 91 patients with CM. At Months 4–6, 62 patients (68.1%) converted from CM to EM; the proportion of converters increased from Month 1 to Month 5. In the overall group of patients, median MHDs decreased from 26.5 (IQR 20–30) to 7.5 (IQR 5–16; P < 0.001) compared with baseline, while median acute medication days decreased from 21 (IQR 16–30) to 6 (IQR 3–10; P < 0.001) and median NRS scores decreased from 8 (IQR 7–9) to 6 (IQR 4–7; P < 0.001). Significant decreases were found both in converters and in non-converters. We found no significant predictors of conversion to EM among the patients’ baseline characteristics. CONCLUSIONS: In our study, two thirds of patients with CM converted to EM during 6 months of treatment with erenumab. MHDs, acute medication use, and headache intensity decreased regardless of conversion from CM to EM.
format Online
Article
Text
id pubmed-7429460
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-74294602020-08-18 Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region Ornello, Raffaele Casalena, Alfonsina Frattale, Ilaria Caponnetto, Valeria Gabriele, Amleto Affaitati, Giannapia Giamberardino, Maria Adele Assetta, Maurizio Maddestra, Maurizio Marzoli, Fabio Viola, Stefano Cerone, Davide Marini, Carmine Pistoia, Francesca Sacco, Simona J Headache Pain Short Report BACKGROUND: Most patients treated with erenumab in clinical practice have chronic migraine (CM). We assessed the rate and possible predictors of conversion from CM to episodic migraine (EM) in a real-life study. MAIN BODY: We performed a subgroup analysis of patients treated with erenumab from January 2019 to February 2020 in the Abruzzo region, central Italy. Treatment was provided according to current clinical practice. For the purpose of the present study, we included patients fulfilling the definition of CM for the three months preceding erenumab treatment and with at least 6 months of follow-up after treatment. We assessed the rate of conversion to EM from baseline to Months 4–6 of treatment and during each month of treatment. To test the clinical validity of conversion to EM, we also assessed the decrease in monthly headache days (MHDs), acute medication days, and median headache intensity on a Numerical Rating Scale (NRS). We included in our study 91 patients with CM. At Months 4–6, 62 patients (68.1%) converted from CM to EM; the proportion of converters increased from Month 1 to Month 5. In the overall group of patients, median MHDs decreased from 26.5 (IQR 20–30) to 7.5 (IQR 5–16; P < 0.001) compared with baseline, while median acute medication days decreased from 21 (IQR 16–30) to 6 (IQR 3–10; P < 0.001) and median NRS scores decreased from 8 (IQR 7–9) to 6 (IQR 4–7; P < 0.001). Significant decreases were found both in converters and in non-converters. We found no significant predictors of conversion to EM among the patients’ baseline characteristics. CONCLUSIONS: In our study, two thirds of patients with CM converted to EM during 6 months of treatment with erenumab. MHDs, acute medication use, and headache intensity decreased regardless of conversion from CM to EM. Springer Milan 2020-08-15 /pmc/articles/PMC7429460/ /pubmed/32799790 http://dx.doi.org/10.1186/s10194-020-01171-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Ornello, Raffaele
Casalena, Alfonsina
Frattale, Ilaria
Caponnetto, Valeria
Gabriele, Amleto
Affaitati, Giannapia
Giamberardino, Maria Adele
Assetta, Maurizio
Maddestra, Maurizio
Marzoli, Fabio
Viola, Stefano
Cerone, Davide
Marini, Carmine
Pistoia, Francesca
Sacco, Simona
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
title Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
title_full Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
title_fullStr Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
title_full_unstemmed Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
title_short Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
title_sort conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an italian region
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429460/
https://www.ncbi.nlm.nih.gov/pubmed/32799790
http://dx.doi.org/10.1186/s10194-020-01171-w
work_keys_str_mv AT ornelloraffaele conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT casalenaalfonsina conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT frattaleilaria conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT caponnettovaleria conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT gabrieleamleto conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT affaitatigiannapia conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT giamberardinomariaadele conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT assettamaurizio conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT maddestramaurizio conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT marzolifabio conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT violastefano conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT ceronedavide conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT marinicarmine conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT pistoiafrancesca conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion
AT saccosimona conversionfromchronictoepisodicmigraineinpatientstreatedwitherenumabreallifedatafromanitalianregion